Samuel Lucas Dos Santos

Dr. Samuel Lucas Dos Santos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
FRFlavio Pola dos Reis
Flavio Pola dos Reis
LFLucas Matos Fernandes
Lucas Matos Fernandes
LALuis Gustavo Abdalla
Luis Gustavo Abdalla
SCSilvia Vidal Campos
Silvia Vidal Campos
PCPriscila Cilene Leon Bueno de Camargo
Priscila Cilene Leon Bueno de Camargo
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
BACKGROUND: Lung transplantation (LTx) has been discussed as an option for treating irreversible lung fibrosis post-coronavirus disease 2019 (COVID-19), in selected cases. OBJECTIVES: To report on the initial experience and management of end-stage lung disease due to COVID-19 at a national center reference in Brazil. DESIGN AND SETTING: Cohort study conducted at a national reference center for lung transplantation. METHODS: Medical charts were reviewed regarding patients'demographics and pre-COVID-19 characteristics, post-LTx due to COVID-19. RESULTS: Between March 2020 and September 2021, there were 33 cases of LTx. During this period, we evaluated 11 cases of severe COVID-19-related acute respiratory distress syndrome (ARDS) that were potentially candidates for LTx. Among these, LTx was only indicated for three patients ( 9.1%). All of these patients were on venovenous extracorporeal membrane oxygenation ( ECMO), and the procedure that they underwent was central venoarterial ECMO. All three patients were still alive after the first 30 postoperative days. However, patient #1 and patient #2 subsequently died due to fungal sepsis on the 47th and 52nd postoperative days, respectively. Patient #3 was discharged on the 30th postoperative day. CONCLUSIONS: LTx is feasible among these complex patients. Survival over the first 30 days was 100%, and this favors surgical feasibility. Nonetheless, these were critically ill patients.

11 April 2026 in Clinics
Verified
Journal Article
Open access
Anna Luíza Soares de Oliveira RodriguesAnna Luíza Soares de Oliveira Rodrigues
Anna Luíza Soares de Oliveira Rodrigues
FRFlavio Pola dos Reis
Flavio Pola dos Reis
TCThamiris Dias Delfino Cabral
Thamiris Dias Delfino Cabral
SSSamuel Lucas Dos Santos
Samuel Lucas Dos Santos
LFLucas Matos Fernandes
Lucas Matos Fernandes
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Organ preservation at low temperatures has been described since Alexis Carrel's time in 1912. Since then, organs have been stored in a mixture of frozen saline solution and liquid, with a temperature of around 4 °C. Studies suggest higher temperatures may preserve mitochondrial function, allowing for an extended ischemia time. Various systems are commercially available, each with different preservation principles. This study aims to analyze the underlying parameters of each device. A systematic review was conducted using the following databases: PubMed, Embase, and Cochrane Library, searching for clinical trials and observational studies evaluating the use of thermal boxes for lung preservation devices in transplantation. The assessed outcomes were Primary Graft Dysfunction (PGD), ventilation time, length of hospital stay, rejection rate, and survival rate. The search yielded six studies selected based on title and abstract, including 519 lung transplant cases. The preservation systems evaluated were LUNGguard and MYTEMPF. Our studies assessed LUNGguard, with a total of 298 patients. This system maintained an average temperature of 6 °C (4° to 8 °C), and 51 patients developed grade 3 PGD within 72 h. The mean ventilation time was 25.2 h (25 to 25.5 h), and ICU stay ranged from 8 to 9 days. Rejection was observed in 3 out of 18 patients, and hospital survival was reported in 221 out of 231 patients. MYTEMP 65 HC was evaluated in one study with 70 patients, of whom 4 developed grade 3 PGD within 72 h. The mean ventilation time was 49 h, and the length of hospital stay was 25 days. Kaplan-Meier estimated survival was 94 % (HR = 0.65; 95 % CI 0.26 to 1.6). Preservation systems show different performances in lung preservation devices for transplantation. Across available studies, LUNGguard has been reported to maintain temperature stability with corresponding survival findings. Across studies of MYTEMP, lower grade 3 PGD rates have been reported, together with longer ventilation and hospitalization durations, and the device is described as non-transport. Other devices exist on the market, but their data remains unpublished. In summary, ongoing clinical studies with these and other preservation devices are expected to provide new evidence in the near future. As additional data become available, an updated systematic review will help clarify their comparative performance and guide clinical practice.

Verified
Journal Article
Open access
PDF file
SSSamuel Lucas Dos Santos
Samuel Lucas Dos Santos
FRFlavio Pola dos Reis
Flavio Pola dos Reis
LALuis Gustavo Abdalla
Luis Gustavo Abdalla
LFLucas Matos Fernandes
Lucas Matos Fernandes
EOElissa Ayumi Okuno
Elissa Ayumi Okuno
PPPaulo Manuel Pêgo-Fernandes
Paulo Manuel Pêgo-Fernandes
Backgorund\Objectives: Lung transplantation is the definitive treatment for select patients with end-stage pulmonary diseases. However, immunologic sensitization, as measured by calculated panel-reactive antibody (cPRA), poses significant challenges to transplant access and outcomes. This study aimed to evaluate the impact of cPRA on lung transplantation waitlist dynamics in a single-center cohort in Brazil, focusing on its association with waitlist mortality, delisting, and transplantation. Methods: A retrospective cohort study was conducted including all lung transplant candidates listed in our institution between January 2012 and December 2022. Candidates were stratified by cPRA values at listing into five groups: 0%, 0.1–25%, 25.1–50%, 50.1–75%, and 75.1–100%. Primary outcomes included lung transplantation, with secondary outcomes of waitlist mortality and delisting due to clinical deterioration. Statistical comparisons were performed, as appropriate. Results: Of the 411 candidates evaluated, 327 met the inclusion criteria. Among them, 100 (30.6%) were sensitized (cPRA > 0%), with increasing cPRA values correlating with longer median waitlist times (p < 0.01). Although transplantation rates were not statistically different across the cPRA strata (p = 0.277), the group with a cPRA > 75% had the lowest transplant rate (37.5%). Waitlist mortality was significantly higher in candidates with a cPRA > 50% (p = 0.047), whereas delisting rates did not differ across groups (p = 0.722). Conclusions: Elevated cPRA is associated with prolonged waitlist time and increased mortality, reflecting both immunologic and logistical barriers to lung transplantation. These findings support the need for incorporating cPRA into allocation policies and adopting targeted strategies, such as desensitization protocols, to improve equity in transplant access for sensitized patients, particularly in genetically diverse populations. Further multicenter studies are warranted to validate these results and inform policy development.

13 September 2022 in Transplantation
Verified
Journal Article
Open access
CBCarlos E F Belon
Carlos E F Belon
EOElissa A Okuno
Elissa A Okuno
SCSilvia V Campos
Silvia V Campos
ARAscedio J Rodrigues
Ascedio J Rodrigues
ELEvelisse Lima
Evelisse Lima
SSSamuel Lucas Dos Santos
Samuel Lucas Dos Santos